Barretina-Ginesta María Pilar, Quindós María, Alarcón Jesús Damián, Esteban Carmen, Gaba Lydia, Gómez César, Fidalgo José Alejandro Pérez, Romero Ignacio, Santaballa Ana, Rubio-Pérez María Jesús
Medical Oncology Department, Institut Català d'Oncologia (ICO), Department of Medical Sciences, Girona Biomedical Research Institute (IDIBGI). Department of Medical Sciences, Medical School University of Girona (UdG), Girona, Spain.
Medical Oncology Department, Complexo Hospitalario Universitario de A Coruña. Biomedical Research Institute (INIBIC), A Coruña, Spain.
Clin Transl Oncol. 2022 Apr;24(4):625-634. doi: 10.1007/s12094-022-02799-7. Epub 2022 Mar 21.
Endometrial cancer (EC) is the second most common gynecological malignancy worldwide, the first in developed countries [Sung et al. in CA Cancer J Clin 71:209-249, 2021]. Although a majority is diagnosed at an early stage with a low risk of relapse, an important proportion of patients will relapse. Better knowledge of molecular abnormalities is crucial to identify high-risk groups in early stages as well as for recurrent or metastatic disease for whom adjuvant treatment must be personalized. The objective of this guide is to summarize the current evidence for the diagnosis, treatment, and follow-up of EC, and to provide evidence-based recommendations for clinical practice.
子宫内膜癌（EC）是全球第二常见的妇科恶性肿瘤，在发达国家则位居首位[宋等人，《CA：临床医师癌症杂志》71:209 - 249，2021年]。尽管大多数患者在早期被诊断出来，复发风险较低，但仍有相当一部分患者会复发。更好地了解分子异常对于在早期识别高危人群以及对于复发或转移性疾病（其辅助治疗必须个性化）至关重要。本指南的目的是总结目前关于子宫内膜癌诊断、治疗和随访的证据，并为临床实践提供基于证据的建议。
